BÜHLMANN sCAL® turbo 10 Application Notes

10 validated Application Notes for BÜHLMANN sCAL® turbo

Calprotectin is a protein complex composed of S100A8 and S100A9, mainly produced by leukocytes such as monocytes and granulocytes in inflamed tissues. Unlike CRP and ESR which are hepatocyte-dependent acute-phase reactants, calprotectin is released locally at the site of inflammation.

Circulating calprotectin has been implicated in the inflammatory process and the pathogenesis of rheumatoid arthritis (RA) and other rheumatic musculoskeletal diseases (RMDs). Calprotectin levels are higher in patients with certain inflammatory rheumatic diseases than in healthy controls and correlate well with clinical outcomes.

Thus, calprotectin is a promising biomarker for disease activity and severity in these conditions and can even detect subclinical levels of inflammation and predict disease relapse and monitor response to treatment.

— The NEW BÜHLMANN sCAL® turbo is the first turbidimetric serum calprotectin assay which has been validated on clinical chemistry analyzers from all major vendors.

— The NEW BÜHLMANN sCAL® turbo serum calprotectin ensures the best combination of high throughput, cost-efficiency, fast turnaround time, and high accuracy using existing lab infrastructure.

— We have also developed a reliable preanalytical procedure to maximize accuracy and reliability of the BÜHLMANN sCAL® turbo assay.

Available Application  Notes
Manufacturer Analyzer1
Mindray BS-480
Abbott Alinity, Architect
Beckman Coulter AU series
Roche cobas c501/c502, c503, c303, c701/c7022
Siemens Atellica
Thermo Fisher Scientific Indiko Plus
The Binding Site Optilite
1The analyzers mentioned in the table are registered trademarks held by the corresponding manufacturers.
Serum calprotectin is an important biomarker:

in clinical diagnosis and monitoring of rheumatic musculoskeletal diseases (RMDs) such as

       — Systemic Juvenile Idiopathic Arthritis (sJIA) versus other diseases

abstract published in collaboration with German pediatrician Prof. Dirk Föll during EULAR 2023 in Milano

       — Rheumatoid Arthritis (RA) and other related RMDs

in other inflammatory disorders such as:

  •        — Sepsis (ongoing clinical study)
  •        — COVID-19
  •        — Other autoimmune diseases

The BÜHLMANN sCAL® turbo serum calprotectin is a NEW cost-efficient and easy-to-use clinical biomarker complementary to existing established biomarkers such as CRP and ESR used in routine diagnostics. Compared to CRP and ESR, a wealth of clinical data acquired indicates that serum calprotectin is a superior biomarker with higher sensitivity and selectivity.

— Serum calprotectin is released by granulocytes and monocytes in inflamed tissue as compared to systemic inflammation markers like CRP and ESR, which are secreted by the liver, indicating that serum calprotectin potentially better reflects local disease activity.

— Serum calprotectin potentially allows diagnosis of subclinical levels of diseases which is important for predicting clinical onset of disease and therapeutic monitoring.

Unlike assay technologies like chemiluminescence immunosorbent assay (CLIA) and fluorescence enzyme immunosorbent assay (FEIA), the BÜHLMANN sCAL® turbo assay relies on the particle-enhanced turbodimetric immunoassay (PETIA) technology. Most central clinical laboratories are already equipped with clinical chemical analyzers based on PETIA technology. This allows for easy-to-use, robust, and high precision measurements with random access and fast turnaround times without the need for additional complex and costly capital expenditures. PETIA technology also allows for a wide measuring range, relevant to diagnosis, as well as monitoring of rheumatic inflammatory diseases and other inflammatory disorders.